Merck (NYSE:MRK) recently announced promising results from its Phase 3 KEYNOTE-689 trial of KEYTRUDA, presented at the AACR Annual Meeting, which seems likely to have bolstered investor confidence, ...

Ending a 20-year-plus drought, Merck & Co.’s Keytruda demonstrated that its use around surgery can reduce the risk of certain ...

Interim results from a study in China suggest ivonescimab may reduce the risk of death versus Keytruda, but the difference ...

Chinese regulator grants second approval for lung cancer drug ivonescimab, which has outperformed Merck’s Keytruda in phase ...

Merck & Co has announced results from the Phase III KEYNOTE-689 trial of Keytruda (pembrolizumab) as a perioperative ...

A trial by MSK researchers has shown that neoadjuvant treatment with GSK's Jemperli spared 80 percent of patients with dMMR ...

Interim KEYNOTE-689 trial data show that perioperative Keytruda significantly lowers the risk of disease progression or ...

Pembrolizumab combo before/after surgery and radiation significantly improved event-free survival in resectable advanced head ...

Medicenna Therapeutics Corp. ("Medicenna" or the "Company") , a clinical-stage immunotherapy company focused on the development of Superkines targeting cancer and autoimmune diseases, ...

We recently published a list of 10 Most Profitable Blue Chip Stocks to Buy Now. In this article, we are going to take a look ...

The FDA is currently reviewing Merck’s sBLA for Keytruda in head and neck cancer, with a target action date of June 23.

With ivonescimab’s data coming solely from China, its prospects in the U.S., where Summit owns the rights, remain up in the ...